Affiliation:
1. University
2. Department of Biology, Faculty of Natural and Applied Sciences, Ignatius Ajuru University of Education, Rumuolumeni, Port Harcourt, Rivers State, Nigeria
Abstract
Background: The search for new partner drugs to increase the therapeutic activity of existing antimalarial drugs is important because of decreased Plasmodium susceptibility. Amodiaquine (AQ) is an antimalarial drug. Moxifloxacin (MX) is a fluoroquinolone antibiotic with promising antiplasmodial activity. This study evaluated the benefit of MX as a partner drug with AQ for malaria treatment in Plasmodium berghei-infected mice. Methods: Adult Swiss albino mice (28-35g) of both sexes, randomly grouped and inoculated with Plasmodium berghei were used. The mice were treated orally with AQ (10 mg/kg), MX (6 mg/kg) and AQ-MX, respectively using the curative, prophylactic and suppressive protocols. Blood samples were collected and assessed for percentage parasitemia and hematological indices. Liver samples were assessed for histological changes. Mean survival time (MST) was observed in treated mice. Results: The curative, prophylactic and suppressive tests showed that AQ-MX decreased percentage parasitemia with difference observed at p
Publisher
Archives of Current Medical Research
Reference37 articles.
1. 1. World Health Organization. Official records of WHO. No. 184, 23rd WH Assen. Geneva, World Health Organization 1970.
2. 2. Taylor C, Florey L, Ye Y. Equity trends in ownership of insecticides treated nets in Sub-Sahara Africa Countries. Bull. WHO 2017; 95: 322-322.
3. 3. World Health Organization Global technical strategy for malaria 2016-2030
4. 4. World Health Organization. Guideline for the treatment of malaria. Geneva, World Health Organization 2015.
5. 5. Menard D, Dondorp AR.Antimalarial drug resistance: A threat to malaria elimination. Cold spring Herb Pers Med, 2017